Physician profile
Katherine Carias
NPI 1205828282
$3,128.13
in general payments reported to CMS, 2019-2025
24 companies · $496 in 2025
The $496 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $164 · 2021: $378 · 2022: $303 · 2023: $433 · 2024: $621 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459 · Education: $81.14 · Consulting Fee: $10.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.17 |
| Education | $81.14 |
| Consulting Fee | $10.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $914.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $337.83 | 2019-2025 | Nucala, Trelegy Ellipta |
| Pharming Healthcare, INC. | $318.19 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $303.40 | 2019-2024 | Xolair |
| Astrazeneca Pharmaceuticals LP | $197.65 | 2019-2025 | Airsupra, Tezspire |
| Grifols USA, LLC | $178.22 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $147.30 | 2021-2025 | Cuvitru, Hyqvia |
| Alk-Abello, INC | $127.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $117.40 | 2022-2024 | Dupixent |
| Mylan Specialty L.P. | $62.03 | 2022-2023 | Yupelri |
| Adma Biomanufacturing LLC | $45.20 | 2022-2025 | |
| Pfizer INC. | $43.35 | 2021-2022 | |
| Optinose US, INC. | $42.44 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $35.06 | 2022 | |
| Blueprint Medicines Corporation | $34.83 | 2023-2025 | Ayvakit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $34.63 | 2023 | Rexulti |
| Kaleo, INC. | $34.35 | 2020-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $30.55 | 2021-2023 | |
| Amgen INC. | $28.74 | 2023-2025 | Tezspire |
| Lilly USA, LLC | $22.65 | 2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $19.42 | 2024 | |
| Biocryst US Sales Co., LLC | $19.25 | 2025 | Orladeyo |
| Otsuka America Pharmaceutical, INC. | $17.13 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Carias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.